Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

Marie Skłodowska-Curie Action · Ended early

MirrorBody Discovery, total chemical synthesis, and validation of “mirror-image” D-Nanobodies

Coordinator
Centre National De La Recherche Scientifique CNRS, France
Runs
1 August 2022 to 31 July 2024
Status
Ended early
EU funding
€196k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101066174

What the project is doing

In the project's own words, from its summary on CORDIS.

The central role of molecularly-targeted therapeutics and imaging probes in translational research entails the development of an ever-growing arsenal of “chemical biologics” endowed with optimal in vivo properties. In this regard, mAbs and their derivatives (e.g. ADCs) still suffer from unsettled drawbacks involving difficulties in production and characterization, leading to heterogeneous conjugates in terms of size, potency and toxicity.

Chemical modifications on mAbs are highly unreliable due to their complex structure: a central problem in this discipline, where heterogeneous drug-to-antibody ratio (DAR) and conjugation site represent significative limitations. Immunogenicity is a major drawback which affects humanized, as well as fully-human mAbs, and is exacerbated by long half-lives. Cases of unwanted activation of the immune system reportedly degenerated to life-threatening conditions such as acute anaphylaxis, serum sickness and cytokine release syndrome.

Their bulky size (≈150 kDa) hinders their extravasation, impairing their efficiency to enter tumors. Nanobodies (Nbs) are the smallest naturally-derived antibody fragments (≈13-14 kDa) that retain antigen-binding affinities in the same range of mAbs (nM to pM affinity range) while having extremely reduced half-lives ( ≈ 15 min.) when not bound to their target, thanks to a fast renal excretion. MirrorBody intends to push the boundaries of targeted “chemical biologics” via an interdisciplinary approach that exploits both immunology and synthetic chemistry techniques for the generation of synthetic D-nanobodies that bind natural L-targets with high affinity.

Such unprecedented synthetic D-Nbs will be endowed with improved biocompatibility, and will enable “plug-and-play” approaches for the controlled conjugation of diverse moieties.

Topics

Who is involved

OrganisationCityCountryRole
Centre National De La Recherche Scientifique CNRSParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI